Spotlight On... Supreme Court about to hear Stryker Corporation v. Zimmer patent case; FDA approves 4 CRT leads for Boston Sci; TransMedics takes warm perfusion to liver transplants; and more...

Two device bigwigs are duking it out at the Supreme Court Tuesday. The outcome of Stryker Corporation v. Zimmer will influence patent cases across multiple industries. The court will rule on Stryker's ($SYK) argument to triple the $70 million it was awarded from Zimmer Biomet ($ZBH) for infringing the patent of one of its devices, the Pulsavac Plus, which is used to clear debris during orthopedic surgery. Here's the Petition for a Writ of Certiorari | Previous coverage from FierceMedicalDevices

@FierceMedDev: ICYMI yesterday: FDA advisory panel votes against recommending approval of Medtronic spine implant. Article | Follow @FierceMedDev

@StacyALawrence: Philips unveils wearable, wireless vitals patch that goes from hospital to home. Story | Follow @StacyALawrence

@EmilyWFierce: op employers aim at Big Pharma with group project to bring down drug costs. More from FiercePharma | Follow @EmilyWFierce

> The FDA approved Boston Scientific's ($BSX) X4 Quadripolar Left Ventricular leads for its Acuity cardiac resynchronization therapy (CRT) device. More

> TransMedics is starting a pivotal trial of its ex-vivo warm perfusion donor organ technology for use in liver transplantation. More

> AVX has asked a Delaware federal judge to reverse a $37.5 million patent infringement award to Greatbatch. More

Biotech News

@FierceBiotech: Ignyta dumps some Teva cancer drugs to focus on its top prospects. Report | Follow @FierceBiotech

@JohnCFierce: Incredible what a horrible, awful, no good year this has been for Duchenne MD patients and families. Nothing but rout and disaster. | Follow @JohnCFierce

> Codexis sues a rival over 'brazen' patent infringement. News

> Sanofi cuts research staffers in Boston as reorganization looms: report. Item

> Ignyta dumps some Teva cancer drugs to focus on its top prospects. Article

Pharma News

@FiercePharma: Japan's MHLW to review 3 drugs, 2 devices for Sakigake list. FiercePharmaAsia article | Follow @FiercePharma

> Those PBM moves pharma loves to hate? They work, CVS says--so get used to them. More

> Prosecutors raid Novartis South Korea in kickbacks probe. Story

> Pfizer workers, retirees face big tax bills from $160B Allergan deal. Report

> Another snafu for Valeant as internal probe triggers restated earnings. Article

Pharma Manufacturing News

> FDA allows banned China plant to ship chemo API that is in short supply. More

> China halts track-and-trace project because of complains against Alibaba. Item

> GSK opens expanded operations, adds 55 jobs, in Scotland. Report

> EMA cites another China plant for manufacturing, data flaws. Story

> Zydus Cadila gets 'first' FDA approval to ship from Ahmedabad plant. Article

Drug Delivery News

> FDA approves UCB epilepsy med, allows administration without titration. Report

> Saudi researchers show linking drugs to nanotubes helps them battle breast cancer. Story

> Two HIV-preventing vaginal ring studies promise protection for women in developing countries. More

> Amgen gets rights to Unilife's wearable and injectable devices for $75M. Item

> Capsugel to manufacture inhaled particle candidates developed by Pulmatrix. Article

Pharma Asia News

> Japan's MHLW to review 3 drugs, 2 devices for Sakigake list. Item

> BMS PhIII hep C combo results a milestone for China plans. More

> Novartis South Korea office target of bribery probe. Report

> China's IMPACT Therapeutics raises $10M in Series B funding. Story

> China's system to track fake drugs put on hold, CFDA says. Article